Nonclinical Efficacy Testing » Non-Clinical CROs and Agencies » UNITECH Co.,Ltd.

UNITECH Co.,Ltd.

Table of Contents
Table of Contents

UNITECH Co.,Ltd. has evolved from genetic research to drug discovery support and conducts nonclinical studies under non-GLP conditions—covering pharmacology (PD), toxicology, and pharmacokinetics—through in-house contract services. With a high level of expertise and a rapid testing framework, UNITECH Co.,Ltd. provides strong support from the early stages of new drug development.

Features of UNITECH Co.,Ltd.’s Non-Clinical Contract Testing Services

Contract-based testing from disease-model creation

UNITECH Co., Ltd. has extensive experience establishing a variety of mouse disease models and conducts pharmacology, toxicology, and pharmacokinetic studies in an integrated manner. With diverse models addressing inflammatory and immune diseases, metabolic diseases, cancer, and cardiovascular diseases, the team can design rigorous studies aligned with specific research objectives.

By handling the entire workflow in-house—from model generation to study execution and data analysis—UNITECH Co., Ltd. maintains stable quality while enabling flexibility.

Support for multifaceted pharmacology, toxicology, and pharmacokinetics

UNITECH Co.,Ltd. conducts pharmacology, toxicology, and pharmacokinetic studies in both in vitro and in vivo systems. In addition to efficacy evaluations using genetically engineered mice and other disease models, the organization performs non-GLP safety assessments such as acute toxicity and repeated-dose toxicity studies, as well as pharmacokinetic evaluations using LC–MS/MS.

Testing coverage spans from the discovery stage of drug candidates through preclinical development.

Flexible support from the study-design stage

A contracting model from the earliest stages allows UNITECH Co.,Ltd. to propose study designs and analytical methods tailored to each request, including disease-model selection and adjustment of analysis items.

A stepwise approach can be provided according to study scale—from initial evaluations in a small number of animals to full confirmation of drug efficacy—optimizing study content as research and development progress or policies change.

Examples of Disease Models Available at UNITECH Co.,Ltd.

Extensive experience with genetically engineered mouse models

Backed by a track record of producing more than 1,300 lines of genetically engineered mice, the company can develop a wide range of disease models. Specifically, models can be constructed to meet varied research needs, including cancer models, Alzheimer’s disease models, organ-specific transgenic (Tg) mice (e.g., cardiac muscle, kidney), conditional KO/KI mice, null KO, BAC-Tg, and point-mutation models.

Even when production is challenging, UNITECH Co.,Ltd. provides integrated in-house support from vector construction through ES cell production and analysis. A complete support framework—from design to delivery—is in place, and the company’s policy is to “not abandon a project unless cell production is impossible.”

Reference: UNITECH Co.,Ltd.'s official website (https://www.uniqtech.co.jp/drug-discovery/)

UNITECH Co.,Ltd. Non-Clinical Case Studies

Anti-tumor evaluation model using human colon cancer cells

A case study in which human colon cancer cells (HT-29) were subcutaneously transplanted into nude mice to evaluate anti-tumor efficacy. Tumor growth was measured periodically to confirm the efficacy of the test article under non-GLP conditions.

By utilizing a cancer xenograft model, screening can be performed in an evaluation environment closer to clinical conditions. This model is effective for selecting candidate compounds in the early stages of drug discovery because it can also be used to evaluate tumor shrinkage and toxicity.

Reference: UNITECH Co.,Ltd.'s official website (https://www.uniqtech.co.jp/mouse-production-results/)

UNITECH Co.,Ltd. Information

Address367-2 Kashiwa, Kashiwa-shi, Chiba, Japan
Tel04-7164-6899
Websitehttps://www.uniqtech.co.jp/

3 Recommended Contract Research Organizations
for Non-Clinical Studies
— by Target goal and Expertise

In non-clinical development, the choice of contract research organization shapes the quality of the data and the time it takes to reach the next decision. Below, three CROs are introduced by the type of study they support: pharmacology (efficacy) studies, safety studies, and pharmacokinetic (PK/PD) studies. Each summary describes the services the company offers so that you can match a provider to your target and development objective.

Pharmacology (Efficacy) StudiesDisease-Relevant Models for
Translational Drug Evaluation
SMC Laboratories, Inc.
Reference: SMC Laboratories, Inc. official website (https://www.smccro-lab.com/)

SMC Laboratories, Inc.

SMC Laboratories is a specialized non-clinical CRO focused on in vivo pharmacology and efficacy studies using disease-relevant animal models, particularly in fibrosis, inflammation, metabolic diseases, and oncology.

Areas of Expertise
Disease-Relevant Model Portfolio

SMC Laboratories offers models covering the liver, lung, kidney, intestine, and oncology. Its portfolio includes the proprietary STAM™ model for MASH, fibrosis, and hepatocellular carcinoma.

Study Design Based on Target Biology

Study plans are developed around the target biology, mechanism of action, disease stage, and development objective. Pharmacological endpoints can be combined with histopathology, biomarkers, and disease-specific readouts.

Support from Target Validation to Proof of Concept

With experience from more than 1,000 studies for clients in 30 countries, SMC Laboratories supports programs from target validation and candidate selection through in vivo proof-of-concept studies.

Safety StudiesComprehensive Safety Assessment for
Preclinical Development
Charles River Laboratories
Reference: Charles River Laboratories official website (https://www.criver.com/)

Charles River Laboratories

Charles River provides non-clinical toxicology and safety assessment services for programs ranging from exploratory safety studies to IND-enabling development.

Areas of Expertise
General Toxicology Across Study Designs

Services include single- and repeat-dose toxicology, dose-range finding, and general toxicology studies across multiple species and administration routes.

Non-GLP and GLP Study Support

Charles River supports both non-GLP and GLP studies, allowing sponsors to progress from early safety characterization to studies intended for regulatory submissions.

Integrated IND-Enabling Safety Assessment

Toxicology studies can be integrated with toxicokinetics, clinical pathology, histopathology, and safety pharmacology to support interpretation and IND-enabling safety packages.

Pharmacokinetic (PK/PD) StudiesConnecting Drug Exposure with
Pharmacological Response
Inotiv
Reference: Inotiv official website (https://www.inotiv.com/)

Inotiv

Inotiv provides integrated PK/PD, DMPK, and bioanalytical services to characterize drug exposure and its relationship with pharmacological response.

Areas of Expertise
Pharmacokinetic Characterization

PK studies characterize exposure, half-life, clearance, and other pharmacokinetic parameters needed to understand how a candidate behaves in the selected model.

Exposure–Response Evaluation

Pharmacokinetic data can be combined with pharmacodynamic endpoints and bioanalysis to evaluate the relationship between drug exposure and pharmacological response.

Integrated DMPK and Development Support

Integrated DMPK, pharmacology, and safety information supports candidate comparison, dose selection, dosing-frequency optimization, and decisions about subsequent preclinical development.

By Therapeutic Area
Disease Animal Models
and Reviews
Proven Capability, Expertise and Track Record
Top 3 Non-Clinical CRO Services